Cantor Fitzgerald Predicts Stronger Earnings for GH Research

GH Research PLC (NASDAQ:GHRS) – Equities research analysts at Cantor Fitzgerald raised their FY2025 EPS estimates for shares of GH Research in a note issued to investors on Tuesday, March 4th. Cantor Fitzgerald analyst C. Duncan now forecasts that the company will post earnings of ($0.79) per share for the year, up from their previous estimate of ($0.80). Cantor Fitzgerald currently has a “Overweight” rating and a $14.00 target price on the stock. The consensus estimate for GH Research’s current full-year earnings is ($0.80) per share.

Several other equities analysts have also weighed in on the stock. HC Wainwright restated a “buy” rating and set a $40.00 price target on shares of GH Research in a research report on Monday, January 27th. Canaccord Genuity Group dropped their price objective on GH Research from $31.00 to $28.00 and set a “buy” rating on the stock in a report on Monday, November 18th. Finally, Stifel Nicolaus raised their price target on GH Research from $18.00 to $32.00 and gave the company a “buy” rating in a report on Thursday, February 27th. Five research analysts have rated the stock with a buy rating, According to MarketBeat, the stock currently has a consensus rating of “Buy” and a consensus target price of $30.60.

GH Research Stock Performance

Shares of NASDAQ:GHRS opened at $10.55 on Thursday. GH Research has a 52-week low of $6.00 and a 52-week high of $20.50. The business’s 50 day simple moving average is $10.73 and its two-hundred day simple moving average is $9.20. The firm has a market cap of $548.90 million, a P/E ratio of -13.35 and a beta of 0.94.

GH Research (NASDAQ:GHRS) last issued its quarterly earnings data on Thursday, February 27th. The company reported ($0.17) earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of ($0.23) by $0.06.

Institutional Trading of GH Research

Institutional investors have recently modified their holdings of the stock. BNP Paribas Financial Markets purchased a new stake in GH Research during the 4th quarter worth approximately $44,000. Two Sigma Investments LP bought a new stake in shares of GH Research in the 4th quarter worth $117,000. Millennium Management LLC bought a new stake in GH Research in the fourth quarter worth approximately $145,000. AdvisorShares Investments LLC increased its position in GH Research by 15.4% during the fourth quarter. AdvisorShares Investments LLC now owns 36,011 shares of the company’s stock worth $252,000 after buying an additional 4,806 shares during the last quarter. Finally, Northern Trust Corp grew its stake in shares of GH Research by 26.8% in the 4th quarter. Northern Trust Corp now owns 40,834 shares of the company’s stock valued at $286,000 after purchasing an additional 8,641 shares during the period. Hedge funds and other institutional investors own 56.90% of the company’s stock.

GH Research Company Profile

GH Research PLC, together with its subsidiary GH Research Ireland Limited, engages in developing various therapies to treat psychiatric and neurological disorders. It is involved in the development of 5-Methoxy-N,N-Dimethyltryptamine (5-MeO-DMT) therapies for the treatment of patients with treatment-resistant depression (TRD).